Bladder preservation in muscle-invasive bladder cancer (MIBC) is evidence-based, patient-centered, and underutilized
The latest @IBCG_BladderCA consensus in @EUplatinum offers global expert recommendations on when, how, and for whom bladder-sparing strategies are appropriate 🧵1/5
🏛️ The backbone of bladder preservation is Trimodal Therapy (TMT):
🔹 Maximal TURBT
🔹 Radiation therapy
🔹 Concurrent chemo (cisplatin, 5-FU + MMC, gemcitabine, or carbogen + nicotinamide)
TMT can offer survival outcomes on par with cystectomy for well select patients @AlisonBirtle @Prof_Nick_James @Uromigos @scserendipity1 @DrFelixGuerrero 🧵2/5
@IBCG_BladderCA @EUplatinum @siadaneshmand @pjhensley11 @nnavai @JanetKukreja @WesKassouf @DrRosenbergMSK @urotoday @SWilliams_MD @TomFlaigMD @BladderCancerUS Who qualifies for TMT?
✅ Unifocal cT2 tumor
✅ No multifocal CIS
✅ No hydronephrosis
✅ Good bladder function
❗But even patients with cT3, CIS, or hydronephrosis should not be automatically excluded -> salvage RC is still option 🧵3/5